Organon
Organon & Co is an American global healthcare company focused on women's health, biosimilars, and established prescription medicines. The company manufactures and markets contraception products, fertility treatments, biosimilar therapies, and cardiovascular and respiratory medicines spun off from Merck & Co. Main revenue drivers consist of global commercial sales of Nexplanon, NuvaRing, biosimilars, and legacy established prescription pharmaceuticals. Organon serves gynecologists, fertility specialists, hospital networks, prescription pharmacies, and female patients across North America, Europe, Asia, and Latin America. The company holds a market-leading global position in women's health therapeutics and reproductive health solutions. Headquartered in Jersey City, New Jersey, Organon & Co is listed on the New York Stock Exchange.
9 of the funds FundTelligence covers report a position in Organon.
- Legal name
- Organon & Co
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
Funds holding Organon
- Storebrand Like Muligheter — Storebrand · 0.55 % (full portfolio disclosed, October 2026)
- Schroder ISF Carbon Neutral Credit — Schroders · 0.45 % (full portfolio disclosed, June 2026)
- Schroder ISF Sustainable Global Multi Credit — Schroders · 0.15 % (full portfolio disclosed, December 2025)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)
- Mercer Global High Yield Bond Fund — Mercer · 0.05 % (full portfolio disclosed, December 2025)
- DNB Global Enhanced Small Cap — DNB · 0.05 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)
- Nordea Global Dividend — Nordea Funds · 0.0 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.